Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — ChromaDex — Investor Presentation (January 2015)
42 slides from Niagen Bioscience's investor presentation, Jan 12, 2015
Slide 1: Investor Presentation January 2015
©) ChromaDex January 2015 Investor Presentation
Slide 2: Disclaimers
~ is# Disclaimers Safe Harbor ‘This presentation and other writen or orl statements made from time to time by representatives of ChromaDex contain forwardJooking statements” within the cd, and Secion ie of he Securties Exchange Act of Statements. These aks and uncertainties Incluse those nek factors
Slide 3: ChromaDex at a Glance
ChromaDex at a Glance * Founded 1999 by CEO Frank Jaksch * Headquarters: Irvine, CA * Analytical Laboratory: Boulder, CO ~ Acquired in April 2003 from NaPro Irvine, CA BioTherapeutics = * Regulatory Consulting: Rockville, MD - Acquired Spherix Consulting in December 2012 * Employees: Approximately 8
Slide 4: ChromaDex Overview
NIAGEN. -egeKerar plersPure ChromaDex Overview ChromaDex is an innovative ingredient technology company currently commercializing four patented and_ proprietary ingredient technologies which in aggregate address multi-billion- dollar markets. ProC3G. Gyanidin-3-glucoside J ChromaDex's unique busines
Slide 5: The Natural Products Chemistry Business is a Revenue-generating Platform
’ The Natural Products Chemistry Business is a Revenue-| 5 : generating Platform with 15 Years of Expertise in the Ca Natural Products Industry Natural product Analytical & ean a fine chemicals chemistry-based services Oneonta sevice’ e 4 ® Largest phytochemical ® Analytical testing of ® A global le
Slide 6: The Natural Products Chemistry Business is Positioned for Growth
The Natural Products Chemistry Business is | 6 Positioned for Growth Increased consumer demand — natural products industry expected to reach $243B by 2015" t Increased R&D by global blue-chip players — e.g. Pepsi Global Nutrition Group, Nestle Health Sciences t Increased regulatory scrutiny — FDA im
Slide 7: ChromaDex's Unique Business Model
ChromaDex’s Unique Business Model [7 Naturalproducts » Established and growing brand Chemistry Business « Thousands of customers worldwide Established Customers| POA iS) rest » University research Provides Market Customer order flow SUT - Market trends Gargilt pNBTY | PEPSICO KRAFT. » Proprietary pr
Slide 8: ChromaDex's Unique Strategy Gives it First-mover Advantages
ChromaDex’s Unique Strategy Gives it First-mover le Advantages in Acquiring Patented Ingredient Technologies Access to Research > Insight to Consumer ™ Activity... Markets... i. / Over 250 University & Research Over 1500 Industry Customers \ / Institute customers \ if Dartmouth /NBTY | KRAFT | \ San
Slide 9: ChromaDex Discovers, Acquires, & Develops Early-stage Ingredient Technologies
ChromaDex Discovers, Acquires, & Develops Early-stage j=® Proprietary Ingredient Technologies and Commercializes them in Multi-Billion-Dollar Markets 9 Develop \ ‘Commercialize Discover novel, early-stage Exclusively license Develop ingredient Commercialize in multi-billion- Ingredient Technologies,
Slide 10: Ingredient Market Opportunity
Ingredient Market Opportunity | 10 Novel Market [Addressablefll Sales Ingredients Size Mi Market Size fl— Channels Supplement MLM leas eed Me SPs Nutrition NIAGEN. Retail Functional Food & Beverage DTC pleréPure Pharmaceutical ProC3G.}-——Siiienne Gyanidin-3-glucoside hysician Medical Food Internet “
Slide 11: NIAGEN is the First and Only Commercially Available Nicotinamide Riboside
ChromaDex’s NIAGEN™ is the 15* and Only [11 Commercially Available Nicotinamide Riboside NIAGEN. » ChromaDex launched NIAGEN™ in May 2013 ® Nicotinamide Riboside (NR) is a compound found naturally in milk and shown to boost nicotinamide adenine dinucleotide (NAD+) levels. NAD+ is a critical compound
Slide 12: NIAGEN is a Platform Ingredient Applicable in Numerous Multi-Billion Dollar Markets
NIAGEN™ is a Platform Ingredient Applicable in | 12 Numerous Multi-Billion Dollar Markets Infant Formulas Market Size - $8B Dietary Supplements THOF Market Size - $34B Sports Nutrition \ Market Size - $58 ilk NIAGEN. Commercialization H Opportunities in Multi-Billion-Dollar —— Markets =a Medical Foo
Slide 13: Collaborative Agreements with Prestigious Universities for Research on NIAGEN
» NIAGEN. ChromaDex has Collaborative Agreements with Numerous Prestigious Universities for Research on NIAGEN™ HARVARD ascent ULB ks MEDICAL SCHOOL = Washington University in StLouis ) | =m Massachusetts MAYO | | Institute of CLINIC Technology Gy ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE @m L ee fii
Slide 14: NIAGEN Consumer Products
NIAGEN. NIAGEN™ Consumer Products \44
Slide 15: $62 Million Ingredient Agreement with 5LINX
In January 2014, ChromaDex Announced a | 15 $62 Million Ingredient Agreement with 5LINX® 5LINX” ‘The premier business opportunity offering essential products & services people use everyday Four-year ingredient supply and brand licensing agreement valued at approximately $62 million. + SLINX ® purcha
Slide 16: Case Study: ChromaDex Model in Action - NIAGEN
Case Study Develop ~ ChromaDex Model in Action - NIAGEN™ NIAGEN) | 16 / Commercialize 2006: ChromaDex becomes aware of NR research material 2011: In July, Licensed Comell patents 2012: In July, Licensed Dartmouth patents 2 March, Licensed Washington University patents with Thome Research in for 3 ye
Slide 17: PURENERGY is Poised to Revolutionize the Energy Beverage Market
PURENERGY?® is Poised to Revolutionize the |17 é Energy Beverage Market es Ry = plerePure + Caffeine = ee ® By cocrystallizing caffeine with ChromaDex's pTeroPure ® pterostilbene, caffeine’s energy boost is sustained for at least 6 hours’ * PURENERGY® also results in a more gradual finish, avoiding
Slide 18: Caffeinated Energy Products Under Increased Regulatory and Political Scrutiny
Caffeinated Energy Products Have Been Coming Under [18 f Increased Regulatory and Political Scrutiny Regarding the Possible Risks of Consuming High Amounts of Caffeine March 2012 ~ a Chicago City Alderman proposed banning energy drinks with at least 180 milligrams of caffeine. ‘October 2012 - U.S. S
Slide 19: PURENERGY Clinical Results - 2013
PURENERGY ® Clinical Results - 2013 |19 fr PUPENERGY ~“ The cross-over, clinical study compared the cocrystallized caffeine in PURENERGY ® with ordinary caffeine. The findings of the study showed: PURENERGY® delivers almost 30% more caffeine into the blood than ordinary caffeine. The rate of caffein
Slide 20: PURENERGY Consumer Products
PURENERGY® Consumer Products Hi5B00sT ASSAULT PURENERGY
Slide 21: Blueberries Contain the Powerful Antioxidant Pterostilbene
Blueberries Contain the Powerful Antioxidant |24 Pterostilbene. ChromaDex has Commercialized its IP-backed and Clinically-studied Brand, pTeroPure® plerPure pTeroPure® is ChromaDex's branded pterostilbene * Pterostilbene is a phytoalexin (plant defense system) found naturally in blueberries, but onl
Slide 22: pTeroPure Phase 2/3 Clinical Study on Blood Pressure
pTeroPure® was Evaluated in a Phase 2/3 Clinical | Study Which Showed Statistically Significant Results for its Ability to Lower Blood Pressure plersPure 22 Clinical trial completed at the University of Mississippi Double-blind, randomized, placebo-controlled, IRB-reviewed 80 patients, 4 arms. Eight
Slide 23: pTeroPure Success
pTeroPure® Success | 23 Ry plerePure » Launched pTeroPure® brand in Sept. 2010 » First ChromaDex branded ingredient + 40+ products containing pTeroPure® on the market today Hearts é FIZ,
Slide 24: ProC3G - Anthocyanin
ProC3G ® - Anthocyanin l24 ProC3G. Ganthopure Gyanidin-3-glucoside Overview * Anthocyanins are compounds responsible for the deep purple color in berries, flowers, black rice and other botanicals * Specific anthocyanins have been studied more extensively and have shown promising health benefits — e.
Slide 25: Grew 160% Year-Over-Year
| 26 Grew 160% Year-Over-Year > Net ingredient sales (NIS) for Q3 2014 were $2.0 million, up 160% as compared to Q3 2013 NIS of $780K > Total company net sales in Q3 2014 were $4.14 million up 52% as compared to Q3 2014 in Millions Three Three Nine Nine 42 Months months months Months © Months Ending
Slide 26: ChromaDex Ingredient Patent Portfolio
ChromaDexe Ingredient Patent Portfolio a8 © vnsspaut Patent © Patontoensing Technology Status Ingredient OD icsinarice rosie NIAGEN. a or @ Prerostilbene pleréPure D se0cyenins ProC3G Gonthooue
Slide 27: ChromaDex Ingredient Development Pipeline
ChromaDex Ingredient Development Pipeline Product Potential Benefits Year Launched in Model Pipeline Product 1 Immunity 2015 Pipeline Product 2 Beta-Glucan 2015 Pipeline Product 3 NAD Metabolite 2016 Pipeline Product 4 NAD Metabolite 2016 Pipeline Product 5 NAD Metabolite 2016 Pipeline Product 6 Liv
Slide 28: Following the Model of Other Ingredient Technology Companies
ves <= ChromaDex is Following the Model of Other =| ~~ Ingredient Technology Companies ‘Acquired by DS $1.08B in 20 E Po, Acquired by DSM for NUTRTIONS Fish Oil omega-3. $550M in July 2012 = NEPTUNE Krill Oil omega-3 Market cap $150-$250M fortitech Ingredient Acquired by DSM for $634M in 2012 re) Da
Slide 29: Strategic Investment from DSM Venturing in October 2013
ChromaDex Received Strategic Investment |29 from DSM Venturing in October 2013 DSM BRIGHT SCIENCE. BRIGHTER LIVING. » $2.5 million common stock investment at $0.85/share » Demonstrated DSM’s confidence in the future of ChromaDex as well as its unique business model of acquiring and commercializing n
Slide 30: ChromaDex SAB
| 30 ChromaDex® SAB 224 ChromaDex established its first formal Scientific Advisory Board (SAB) in July 2014 Nobel Laureate Professor Roger Kornberg joined as Chair The other SAB members are: + Dr. Charles Brenner, Professor of Biochemistry, University of lowa (formerly Dartmouth), one of the NR inve
Slide 31: ChromaDex Highlights
< Ce Focused Expertise Ingredient Technology Portfolio NIAGEN ms PURENERGY plerPure ProC3G Cyanidin-3-glucoside 4 Se: ChromaDex® Highlights [31 ChromaDex's natural products chemistry business continues to grow at a steady rate as it has over the past 15 years. Its expertise in the natural products i
Slide 32: Additional Company Information
Additional Company Information APPENDIX | 32
Slide 33: Founded ChromaDex in 1999
| 33 Founded ChromaDex in 1999 Int Subsidiaries Manager at Phenomenex Expertise in analytical chemistry, productdevelopment Recognized industry expert, most recently appearing on Dateline NBC's Hansen Files regarding quality testing in the natural products industry Board of Directors, Natural Produc
Slide 34: ChromaDex Ingredient Technology Portfolio
Clinical Branded ingredient —|_ Compound Monetization Dietary Food & Supply Safety __Development_ Supplements _ Beverage eS ChromaDex® Ingredient Technology Portfolio | 34 gs Animal Skin Pharma Health Care pleréPure vv °@ ° yanidin-3-gocoside v v v v @ ie) VvoO Pipeline of Next-generation products f
Slide 35: Shareholder Summary
Shareholder Summary | 35 Percent Shareholder Number of Shares Ownership! Dr. Phillip Frost 15,252,937 14.26% Opko Health, Inc. (NYSE:OPK) 1,833,333 1.71% DSM Venturing B.V. 2,941,176 2.75% Frank L. Jaksch Jr. (Founder, CEO, Director) 8,248,320 711% Other Directors and Officers 18,589,994 17.38% Tota
Slide 36: Balance Sheets
| 36 Balance Sheets" ‘Soptember 27, 2014 December 28, 2013, Assets Current Assets Cash $ 4,203,758 § 2.261.336 Trade and cther receivables 2,528,638, 1,053,793, Inventories 2,286,086, 2,204,125, Prepaid expenses and other assets 294,296 271,445 Total current assets 6312.78 5,790,699 Leasehold Improv
Slide 37: Statements of Operations
Statements of Operations’ sy For the Nine Month Periods Ended September 27, 2014 and September 28, 2013 ‘September 27, 2014 September 28, 2013 Sales, net $s 11,070,002 § 7,750,668 Cost of sales 7,163,282 5,375,903. Gross profit 3,908,720 2,383,765 (Operating expenses: Sales and marketing 4,884,777 1
Slide 38: Statements of Cash Flows
Statements of Cash Flows! For the Nine Month Periods Ended September 27, 2014 and September 28, 2013, Cash Flows From Operating Activities Net loss ‘Adjustments to reconcile net loss tonet cash Used in operating activites: ‘Changes in operating assets and lables: Net cash used in operating activitie
Slide 39: Non-GAAP Presentation Reconciliation
| 39 Non-GAAP Presentation Reconciliation’ Consaldated Statements of Operations Us GAP) ‘3Months Ended Sep. 27, 2014and Sep. 28 2013, Effects of Non-cash Charges associated with ‘Sharebased Compensation Expense ‘3Months Ended Sep. 27, 2014 and Sep. 28 2013 Consolidated Statements of Operations Exdud
Slide 40: Non-GAAP Presentation Reconciliation
Non-GAAP Presentation Reconciliation’ Consolidated Statements of Operations (Us GAAP) ‘9Mlonths Ended Sep. 27,2014 and Sep. 28, 2013, Efets of Non-cash Charges associated with ‘Sharebased Compensation Expense ‘9Monits Ended Sep, 27,2014 and Sep. 28 2013 | 40 Consolidated Statements of Operations xdu
Slide 41: Non-GAAP Presentation Reconciliation
Non-GAAP Presentation Reconciliation’ Consolidated Statements of Operations. Us GAAP) ‘T2Months Ended Dec. 28, 2013 and Dec. 2, 012 Eets ofNon-cash Charges associated with ‘Share-ased Compensation Expense ‘2Months Ended Dec. 28 2013 and Dec. 2, 2012 Consolidated Statements of Operations Excluding Sh
Slide 42: Contact Information
Contact Information ChromaDex Corporation 10005 Muirlands Bivd., Suite G Irvine, CA 92618 Phone: +1-949-419-0288 Fax: +1-949-419-0294 www.chromadex.com Investor Relations ‘Andrew Johnson ChromaDex Phone: +1-949-419-0288 andrewj@chromadex.com | 42